Microneedling with insulin for treating atrophic scars
Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars
This study is testing if using insulin with microneedling can improve the treatment of atrophic scars better than microneedling alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 12 Years to 60 Years |
| Sex | All |
| Sponsor | Alexandria University Academic / other |
| Locations | 1 site (Alexandria) |
| Trial ID | NCT06021275 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of microneedling combined with regular insulin application compared to microneedling alone in treating atrophic scars. The aim is to determine if the regenerative effects of microneedling are enhanced by the topical application of insulin. Participants will include individuals with atrophic scars who meet specific eligibility criteria, and the study will include a control group for better comparison. The interventions will involve microneedling with either insulin or saline as a control.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 12 to 60 years with completely healed atrophic scars.
Not a fit: Patients with a history of hypertrophic or keloidal scars, or those with active infections at the scar site, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a novel treatment option for patients with atrophic scars, potentially improving their appearance and quality of life.
How similar studies have performed: While some studies have explored the use of insulin in scar treatment, this specific approach comparing microneedling with and without insulin is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged 12 to 60 years 2. Atrophic scars (traumatic or surgical) 3. Completely healed scars Exclusion Criteria: 1. Patients with a tendency or history of hypertrophic or keloidal scars 2. Patients who received treatment for their scar in the past 3 months 3. Diabetic patients or those with a history of Dysglycemia 4. Pregnant, or lactating females 5. Patients with active infection at the site of scar 6. Patients currently receiving isotretinoin treatment or in the past month
Where this trial is running
Alexandria
- Alexandria University, Faculty of Medicine — Alexandria, Egypt (Recruiting)
Study contacts
- Study coordinator: Dalia I Halwag, PhD, MD
- Email: daliahalwag@gmail.com
- Phone: +00201224489473
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.